Nature medicine · 2024
Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Volinsky-Fremond Sarah, Horeweg Nanda, Andani Sonali, Barkey Wolf Jurriaan, Lafarge Maxime W, de Kroon Cor D, Ørtoft Gitte, Høgdall Estrid, Dijkstra Jouke, Jobsen Jan J, Lutgens Ludy C H W, Powell Melanie E, Mileshkin Linda R, Mackay Helen, Leary Alexandra, Katsaros Dionyssios, Nijman Hans W, de Boer Stephanie M, Nout Remi A, de Bruyn Marco, Church David, Smit Vincent T H B M, Creutzberg Carien L, Koelzer Viktor H, Bosse Tjalling
Аннотация
Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. Here we developed HECTOR (histopathology-based endometrial cancer tailored outcome risk), a multimodal deep learning prognostic model using hematoxylin and eosin-stained, whole-slide images and tumor stage as input, on 2,072 patients from eight EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal (n = 353) and two external (n = 160 and n = 151) test sets of 0.789, 0.828 and 0.815, respectively, outperforming the current gold standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low-, intermediate- and high-risk groups, respectively, by Kaplan-Meier analysis). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold standard and may help delivery of personalized treatment in EC.